Search

Your search keyword '"Robia SL"' showing total 65 results

Search Constraints

Start Over You searched for: Author "Robia SL" Remove constraint Author: "Robia SL"
65 results on '"Robia SL"'

Search Results

2. Pathological mutations in the phospholamban cytoplasmic region affect its topology and dynamics modulating the extent of SERCA inhibition.

3. Protein carbonylation causes sarcoplasmic reticulum Ca 2+ overload by increasing intracellular Na + level in ventricular myocytes.

4. Phosphorylation of phospholamban promotes SERCA2a activation by dwarf open reading frame (DWORF).

5. Phospholamban inhibits the cardiac calcium pump by interrupting an allosteric activation pathway.

6. Protein carbonylation causes sarcoplasmic reticulum Ca2+ overload by increasing intracellular Na+ level in ventricular myocytes.

7. Mechanisms for cardiac calcium pump activation by its substrate and a synthetic allosteric modulator using fluorescence lifetime imaging.

8. RyR2 Binding of an Antiarrhythmic Cyclic Depsipeptide Mapped Using Confocal Fluorescence Lifetime Detection of FRET.

9. Dilated cardiomyopathy variant R14del increases phospholamban pentamer stability, blunting dynamic regulation of cardiac calcium handling.

10. Micropeptide hetero-oligomerization adds complexity to the calcium pump regulatory network.

11. Regulation of the regulator: Endopeptidase cleavage controls the expression of a micropeptide that regulates SERCA.

12. Primitive Phospholamban- and Sarcolipin-like Peptides Inhibit the Sarcoplasmic Reticulum Calcium Pump SERCA.

13. Inhibitory and stimulatory micropeptides preferentially bind to different conformations of the cardiac calcium pump.

14. Fluorescence lifetime imaging microscopy reveals sodium pump dimers in live cells.

15. The Ile191Val is a partial loss-of-function variant of the TAS1R2 sweet-taste receptor and is associated with reduced glucose excursions in humans.

16. Presenilin 1 is a direct regulator of the cardiac sarco/endoplasmic reticulum calcium pump.

17. Dwarf open reading frame (DWORF) is a direct activator of the sarcoplasmic reticulum calcium pump SERCA.

18. FXYD proteins and sodium pump regulatory mechanisms.

19. Dynamics-Driven Allostery Underlies Ca 2+ -Mediated Release of SERCA Inhibition by Phospholamban.

20. Dimerization of SERCA2a Enhances Transport Rate and Improves Energetic Efficiency in Living Cells.

21. Protein docking and steered molecular dynamics suggest alternative phospholamban-binding sites on the SERCA calcium transporter.

22. Intrinsically disordered HAX-1 regulates Ca 2+ cycling by interacting with lipid membranes and the phospholamban cytoplasmic region.

23. Newly Discovered Micropeptide Regulators of SERCA Form Oligomers but Bind to the Pump as Monomers.

24. Novel approach for quantification of endoplasmic reticulum Ca 2+ transport.

25. Defects in assembly explain reduced antiviral activity of the G249D polymorphism in human TRIM5α.

26. The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy.

27. Redistribution of SERCA calcium pump conformers during intracellular calcium signaling.

28. Skin cells prefer a slower calcium pump.

29. Regulation of Focal Adhesion Kinase through a Direct Interaction with an Endogenous Inhibitor.

30. Dynamic conformational changes in the rhesus TRIM5α dimer dictate the potency of HIV-1 restriction.

31. L30A Mutation of Phospholemman Mimics Effects of Cardiac Glycosides in Isolated Cardiomyocytes.

32. Restrictive Cardiomyopathy Troponin I R145W Mutation Does Not Perturb Myofilament Length-dependent Activation in Human Cardiac Sarcomeres.

33. Cardiac Calcium ATPase Dimerization Measured by Cross-Linking and Fluorescence Energy Transfer.

34. Rheostatic Regulation of the SERCA/Phospholamban Membrane Protein Complex Using Non-Coding RNA and Single-Stranded DNA oligonucleotides.

35. ATP-Binding Cassette Transporter Structure Changes Detected by Intramolecular Fluorescence Energy Transfer for High-Throughput Screening.

36. Acute inotropic and lusitropic effects of cardiomyopathic R9C mutation of phospholamban.

37. A structural mechanism for calcium transporter headpiece closure.

38. Phospholamban C-terminal residues are critical determinants of the structure and function of the calcium ATPase regulatory complex.

39. Restriction of HIV-1 by rhesus TRIM5α is governed by alpha helices in the Linker2 region.

40. Discovery of enzyme modulators via high-throughput time-resolved FRET in living cells.

41. Phosphorylated phospholamban stabilizes a compact conformation of the cardiac calcium-ATPase.

42. 2-Color calcium pump reveals closure of the cytoplasmic headpiece with calcium binding.

43. Serine-910 phosphorylation of focal adhesion kinase is critical for sarcomere reorganization in cardiomyocyte hypertrophy.

44. TRIM5α associates with proteasomal subunits in cells while in complex with HIV-1 virions.

45. Focal adhesion kinase-related nonkinase inhibits vascular smooth muscle cell invasion by focal adhesion targeting, tyrosine 168 phosphorylation, and competition for p130(Cas) binding.

46. Phospholamban binds with differential affinity to calcium pump conformers.

47. Spatiotemporally distinct protein kinase D activation in adult cardiomyocytes in response to phenylephrine and endothelin.

48. Oligomeric interactions of sarcolipin and the Ca-ATPase.

49. Phosphomimetic mutations enhance oligomerization of phospholemman and modulate its interaction with the Na/K-ATPase.

50. Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A.

Catalog

Books, media, physical & digital resources